Long-term efficacy of rasagiline in early Parkinson's disease

Mark F. Lew, Robert A. Hauser, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Tamar Goren, Cheryl J. Fitzer-Attas

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

Original languageEnglish
Pages (from-to)404-408
Number of pages5
JournalInternational Journal of Neuroscience
Volume120
Issue number6
DOIs
StatePublished - May 2010

Fingerprint

Parkinson Disease
Dopamine Agents
Dopamine Agonists
Levodopa
rasagiline
Safety

Keywords

  • Dopamine agonists
  • Efficacy
  • Levodopa
  • Long-term
  • Monotherapy
  • Rasagiline

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lew, M. F., Hauser, R. A., Hurtig, H. I., Ondo, W. G., Wojcieszek, J., Goren, T., & Fitzer-Attas, C. J. (2010). Long-term efficacy of rasagiline in early Parkinson's disease. International Journal of Neuroscience, 120(6), 404-408. https://doi.org/10.3109/00207451003778744

Long-term efficacy of rasagiline in early Parkinson's disease. / Lew, Mark F.; Hauser, Robert A.; Hurtig, Howard I.; Ondo, William G.; Wojcieszek, Joanne; Goren, Tamar; Fitzer-Attas, Cheryl J.

In: International Journal of Neuroscience, Vol. 120, No. 6, 05.2010, p. 404-408.

Research output: Contribution to journalArticle

Lew, MF, Hauser, RA, Hurtig, HI, Ondo, WG, Wojcieszek, J, Goren, T & Fitzer-Attas, CJ 2010, 'Long-term efficacy of rasagiline in early Parkinson's disease', International Journal of Neuroscience, vol. 120, no. 6, pp. 404-408. https://doi.org/10.3109/00207451003778744
Lew, Mark F. ; Hauser, Robert A. ; Hurtig, Howard I. ; Ondo, William G. ; Wojcieszek, Joanne ; Goren, Tamar ; Fitzer-Attas, Cheryl J. / Long-term efficacy of rasagiline in early Parkinson's disease. In: International Journal of Neuroscience. 2010 ; Vol. 120, No. 6. pp. 404-408.
@article{a93fd4caa62c4eb893b6aa221f891f47,
title = "Long-term efficacy of rasagiline in early Parkinson's disease",
abstract = "This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46{\%} were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3{\%} of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.",
keywords = "Dopamine agonists, Efficacy, Levodopa, Long-term, Monotherapy, Rasagiline",
author = "Lew, {Mark F.} and Hauser, {Robert A.} and Hurtig, {Howard I.} and Ondo, {William G.} and Joanne Wojcieszek and Tamar Goren and Fitzer-Attas, {Cheryl J.}",
year = "2010",
month = "5",
doi = "10.3109/00207451003778744",
language = "English",
volume = "120",
pages = "404--408",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Long-term efficacy of rasagiline in early Parkinson's disease

AU - Lew, Mark F.

AU - Hauser, Robert A.

AU - Hurtig, Howard I.

AU - Ondo, William G.

AU - Wojcieszek, Joanne

AU - Goren, Tamar

AU - Fitzer-Attas, Cheryl J.

PY - 2010/5

Y1 - 2010/5

N2 - This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

AB - This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N=398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 ± 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25 of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

KW - Dopamine agonists

KW - Efficacy

KW - Levodopa

KW - Long-term

KW - Monotherapy

KW - Rasagiline

UR - http://www.scopus.com/inward/record.url?scp=77952848015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952848015&partnerID=8YFLogxK

U2 - 10.3109/00207451003778744

DO - 10.3109/00207451003778744

M3 - Article

VL - 120

SP - 404

EP - 408

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 6

ER -